Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018681 (
headache
)
56,091
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Oral steroids can interrupt bouts of cluster
headache
(CH) attacks, but recurrence is frequent and may lead to steroid-dependency. Suboccipital steroid injection may be an effective 'single shot' alternative, but no placebo-controlled trial is available. The aim of our study was to assess in a double-blind placebo-controlled trial the preventative effect on CH attacks of an ipsilateral steroid injection in the region of the greater occipital nerve. Sixteen episodic (
ECH
) and seven chronic (CCH) CH outpatients were included.
ECH
patients were in a new bout since no more than 1 week. After a one-week run-in period, patients were allocated by randomization to the placebo or verum arms and received on the side of attacks a suboccipital injection of a mixture of long- and rapid-acting betamethasone (n=13; Verum-group) or physiological saline (n=10; Plac-group). Acute treatment was allowed at any time, additional preventative therapy if attacks persisted after 1 week. Three investigators performed the injections, while four others, blinded to group allocation, followed the patients. Follow-up visits were after 1 and 4 weeks, whereafter patients were followed routinely. Eleven Verum-group patients (3 CCH) (85%) became attack-free in the first week after the injection compared to none in the Plac-group (P=0.0001). Among them eight remained attack-free for 4 weeks (P=0.0026). Remission lasted between 4 and 26 months in five patients. A single suboccipital steroid injection completely suppresses attacks in more than 80% of CH patients. This effect is maintained for at least 4 weeks in the majority of them.
...
PMID:Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. 1651 78
Craniofacial nociceptive processing in patients (n = 25) suffering from unilateral cluster
headache
was assessed by laser-evoked cortical potentials (LEPs). Latencies and amplitudes of late (N2, P2) and middle-latency (N1) LEPs were measured in chronic (CCH, n = 9) and episodic cluster
headache
(
ECH
, n = 17). In CCH patients on
headache
side N1c occurred later and P2 amplitude was smaller than on the healthy control side. In active periods of
ECH
patients P2 latency was shorter on the
headache
side. In remission periods of
ECH
patients the N2P2 ratio was lower on the
headache
side. In 19 out of 26 examinations in 25
headache
patients LEP deviated from normative data in healthy controls (n = 10) without any specific pattern of altered parameters. LEPs document pathological changes in craniofacial nociception in cluster
headache
. However, there seems to be no pathognomonic deviation pattern that enables reliable diagnosis of cluster
headache
and application of LEPs in further studies of pathophysiological mechanisms.
Cephalalgia
2007 Jun
PMID:Laser-evoked cortical potentials in cluster headache. 1742
Based on recent data about the association between restless legs syndrome (RLS) and migraine, we performed an observational study on the occurrence of RLS in patients affected by primary
headaches
. Two hundred
headache
patients (149 women and 51 men) and 120 (90 women and 30 men) sex-and age-matched control subjects were included. In the
headache
group, migraine without aura (MO) was the most represented
headache
type (n=114), followed by the "mixed" group (n=40) with MO, migraine with aura (MA) and frequent episodic tension-type
headache
(ETTH) in various combinations, and by ETTH alone (n=22). The remaining patients suffered from MA alone (n=10 MA), episodic cluster
headache
(
ECH
n=12) and primary stabbing
headache
(n=2). RLS frequency was significantly higher in
headache
patients than in control subjects (22.4% vs. 8.3, p=0.002) independently of sex, although with a female preponderance (84%) in both groups. More than 60% (n=27) of RLS patients were affected by MO and 30% (n=13) by a combination of two
headache
types (p> or =0.001), with a very low frequency of RLS for the other types of
headache
. No RLS patient had
ECH
. No statistical differences were observed among clinical characteristics of different types of
headache
in groups with and without RLS. In both
headache
and control groups, higher scores for depression and anxiety were more frequent in subjects with RLS compared with those without RLS. Furthermore,
headache
patients with RLS reported sleep disturbances more frequently compared to those without RLS (50.0% vs. 32.7%; p<0.0001) and showed a normal or underweight body mass index. Our data seem to confirm the existence of an association between RLS and primary
headaches
, particularly with migraine, as already demonstrated. The absence of RLS in
ECH
patients is very interesting. Many pathogenetic considerations about links between RLS and primary
headaches
could be given, the most fitting involving dopamine and melatonin.
...
PMID:Restless legs syndrome and primary headaches: a clinical study. 1854 26
Among cephalgias, cluster
headache
(CH) is the rarest and the most disabling, explaining the appellation of "suicide
headache
." Up to 20% of chronic CH reveals to be resistant to pharmacological treatments, in which case interventional procedures should be considered. Many reports evaluated invasive approaches and a wide strand of research is dedicated to the sphenopalatine ganglion. Our paper will now be focused on providing an overview on modern applications on the sphenopalatine ganglion (SPG), their outcomes, and their feasibility in terms of risks and benefits. The group reviewed the international literature systematically for procedures targeting the sphenopalatine ganglion and its branches for episodic and chronic CH, including block, stimulation, radiofrequency, stereotactic radiosurgery, and vidian neurectomy. Seventeen articles fixed our inclusion criteria. Comparing the outcomes that have been analyzed, it is possible to notice how the most successful procedure for the treatment of refractory chronic and episodic CH is the SPG block, which reaches respectively 76.5% and 87% of efficacy. Radiofrequency has a wide range of outcomes, from 33 to 70.3% in CCH. Stimulation of SPG only achieved up to 55% of outcomes in significant reduction in attack frequency in CCH and 71% in
ECH
. Radiosurgery and vidian neurectomy on SPG have also been analyzed. Generally,
ECH
patients show better response to standard medical therapies; nevertheless, even this more manageable condition may sometimes benefit from interventional therapies mostly reserved for CCH. First results seem promising and considering the low frequency of side effects or complications, we should think of expanding the indications of the procedures also to those conditions. Outcomes certainly suggest that further studies are necessary in order to understand which method is the most effective and with less side effects. Placebo-controlled studies would be pivotal, and tight collaboration between neurologists and otorhinolaryngologists should also be central in order to give correct indications, which allow us to expect procedures on the SPG to be an effective and mostly safe method to control either refractory
ECH
or CCH.
...
PMID:Cluster headache: crosspoint between otologists and neurologists-treatment of the sphenopalatine ganglion and systematic review. 3087 13